BIOMAT Database Logo BIOMAT Database Logo

Diabetes-induced Alterations in HDL Subfractions Distribution. 2020

Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
105 Military Hospital with Outpatient Clinic in Zary, Domanskiego 2, 68-200 Zary, Poland.

Diabetes mellitus (DM) due to its increasing prevalence and associated morbidity and mortality has become a serious public health problem. In DM, HDL may lose its beneficial features and become proatherogenic due to its altered biological activity thus increasing cardiovascular risk. The aim of this study was to assess the influence of the presence of diabetes mellitus type 2 and its duration on the distribution of HDL subfractions. Moreover, the effect of statin treatment on HDL subfraction share was analysed in this study. The study group consisted of 50 patients with newly diagnosed DM and 50 persons with DM for longer than 10 years while the control group consisted of 50 healthy volunteers. HDL subfractions were analysed with the use of Lipoprint. We demonstrated progressive worsening of heart functioning and impairment of its structure in the course of diabetes mellitus. Moreover, we observed that HDL-6 subfraction and intermediate HDL fraction are lowest in the group with advanced DMt2 compared to the group with newly diagnosed DM and a healthy control group. Finally, the results of our study indicated the effect of statin treatment on HDL subfractions that seems not to be advantageous. It seems that in patients with diabetes mellitus compromised antiatherogenic properties of HDL, as a result of oxidative modification and glycation of the HDL protein as well as the transformation of the HDL proteome into a proinflammatory protein, increase cardiovascular risk.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors Compounds that inhibit HYDROXYMETHYLGLUTARYL COA REDUCTASES. They have been shown to directly lower CHOLESTEROL synthesis. HMG-CoA Reductase Inhibitor,HMG-CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Reductase Inhibitor,Statin,Statins, HMG-CoA,Inhibitors, HMG-CoA Reductase,Inhibitors, Hydroxymethylglutaryl-CoA,Inhibitors, Hydroxymethylglutaryl-Coenzyme A,Statins,HMG CoA Reductase Inhibitor,HMG CoA Reductase Inhibitors,HMG-CoA Statins,Hydroxymethylglutaryl CoA Reductase Inhibitor,Hydroxymethylglutaryl CoA Reductase Inhibitors,Hydroxymethylglutaryl-CoA Inhibitors,Hydroxymethylglutaryl-Coenzyme A Inhibitors,Inhibitors, HMG CoA Reductase,Inhibitors, Hydroxymethylglutaryl CoA,Inhibitors, Hydroxymethylglutaryl Coenzyme A,Inhibitors, Hydroxymethylglutaryl-CoA Reductase,Reductase Inhibitor, Hydroxymethylglutaryl-CoA,Reductase Inhibitors, HMG-CoA,Reductase Inhibitors, Hydroxymethylglutaryl-CoA,Statins, HMG CoA

Related Publications

Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
Apolipoprotein distribution in plasma HDL subfractions in alcohol consumers.
October 1990, Drug and alcohol dependence,
Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
HDL subfractions, HDL receptors and HDL turnover.
January 1987, Advances in experimental medicine and biology,
Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
Cholesterol distribution between HDL subfractions. A study of 498 subjects.
January 1989, La Ricerca in clinica e in laboratorio,
Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
More on HDL subfractions.
May 1995, The American journal of medicine,
Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
Alterations of HDL cholesterol distribution induced by incubation of human serum.
October 1982, Biochimica et biophysica acta,
Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
LDL and HDL subfractions, dysfunctional HDL: treatment options.
January 2014, Current pharmaceutical design,
Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
[HDL subfractions in post-prandial lipidemia].
December 1993, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
[Plasma HDL subfractions in endogenous hypertriglyceridemia].
March 1999, Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao,
Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
Alterations of HDL subfractions in patients with Balkan endemic nephropathy and in healthy family members.
December 1996, Clinical nephrology,
Marek Femlak, and Anna Gluba-Brzozka, and Beata Franczyk, and Jacek Rysz
HDL subfractions as altered in cancer patients.
January 1995, Journal of pharmaceutical and biomedical analysis,
Copied contents to your clipboard!